Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Amid a market obsessed with artificial intelligence, investment firm Giverny Capital reveals a new position in Hawkins, Inc., a specialty chemicals manufacturer. We examine the rationale behind this contrarian bet and what it says about current market dynamics.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
Palantir Technologies expands its strategic footprint in Asia through a deepened partnership with HD Hyundai, while securing a pivotal role in building sovereign AI data centers across Europe, the Middle East, and Africa with Sovereign AI and Accenture.
Rockwell Automation expands its partnership with Lucid Motors, deploying its FactoryTalk MES software and training programs at Saudi Arabia's inaugural electric vehicle production hub. The move aligns with the Kingdom's Vision 2030, positioning Rockwell as a key player in the region's high-tech manufacturing transformation.
Meta Platforms heads to a Santa Fe courtroom next week to defend itself in a high-stakes lawsuit. The State of New Mexico alleges the social media giant's platforms facilitated the sexual exploitation of minors and harmed their mental health for profit, marking the first such case against Meta to reach a jury.
Amidst a market often captivated by speculative stories, Thermon Group Holdings (NYSE: THR) presents a profile built on profitability, steady growth, and aligned leadership—factors that seasoned investors typically watch for.
A deep dive into Kadant Inc.'s intrinsic value using a Discounted Cash Flow model suggests the stock is trading near its estimated fair value of $273, raising questions about its near-term upside potential amid current market prices.
Linde plc (LIN) shares have shown consistent upward momentum, closing recently at $455. While short-term performance is strong, a deeper valuation analysis reveals a complex picture, with divergent views on whether the stock is a bargain or fully priced.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Marius Borg Høiby, son of Crown Princess Mette-Marit, was arrested on new violent charges days before his rape trial, casting a shadow over the monarchy just as his mother faces renewed criticism over her past association with Jeffrey Epstein.
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.
Africa's largest conglomerate secures a strategic gas supply agreement with Nigeria's state oil firm, a key move supporting national ambitions to leverage vast gas reserves for industrial growth and investment.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
French reinsurer SCOR has expanded its underwriting capacity for Baobab Insurance's cyber policies in Germany and Austria, now covering companies with annual revenues up to €1 billion, marking a strategic push into Europe's industrial cyber risk market.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
While analyst price targets often paint a rosy picture, a deeper look reveals which recommendations are backed by solid business trends and which may be overly optimistic. We examine one fintech disruptor and one industrial stalwart favored by the Street, alongside a retailer facing significant headwinds.
Chinese courts have executed four individuals convicted of running a multi-billion dollar scam and gambling network from Myanmar, responsible for multiple deaths. The move signals Beijing's escalating pressure on Southeast Asia's industrial-scale cybercrime hubs.
In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.
Shares of RB Global (RBA) have retreated slightly in recent trading, yet the industrial auction giant's stock remains on a strong upward trajectory over the past quarter and year. This divergence presents investors with a classic valuation conundrum: is the current price a buying opportunity, or does a lofty P/E ratio signal overextension?
